NASDAQ:CLDX

Celldex Therapeutics - CLDX Stock Forecast, Price & News

$36.56

+1.46 (+4.16%)

(As of 03/24/2023 12:00 AM ET)

Add

Compare

Today's Range: $33.83
▼
$36.87
50-Day Range: $35.10
▼
$46.94
52-Week Range: $19.85
▼
$48.40

Volume: 861,943 shs
Average Volume: 692,944 shs
Market Capitalization: $1.73 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $66.67

Institutional Ownership

Celldex Therapeutics MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 82.3% Upside
$66.67 Price Target
Short Interest: Bearish
7.67% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.47
Based on 4 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($2.58) to ($2.85) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.62 out of 5 stars

Medical Sector

899th out of 1,005 stocks

Diagnostic Substances Industry

12th out of 15 stocks

3.5

Analyst's Opinion

Consensus Rating
Celldex Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $66.67, Celldex Therapeutics has a forecasted upside of 82.3% from its current price of $36.56.
Amount of Analyst Coverage
Celldex Therapeutics has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
7.67% of the outstanding shares of Celldex Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Celldex Therapeutics has a short interest ratio ("days to cover") of 7.5.
Change versus previous month
Short interest in Celldex Therapeutics has recently increased by 4.32%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Celldex Therapeutics does not currently pay a dividend.
Dividend Growth
Celldex Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CLDX.

3.0

News and Social Media Coverage

News Sentiment
Celldex Therapeutics has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Celldex Therapeutics this week, compared to 1 article on an average week.
Search Interest
7 people have searched for CLDX on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.
MarketBeat Follows
3 people have added Celldex Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Celldex Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.70% of the stock of Celldex Therapeutics is held by insiders.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Celldex Therapeutics are expected to decrease in the coming year, from ($2.58) to ($2.85) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Celldex Therapeutics is -15.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Celldex Therapeutics is -15.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Celldex Therapeutics has a P/B Ratio of 5.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Celldex Therapeutics (NASDAQ:CLDX) Stock

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Receive CLDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CLDX Stock News Headlines

March 23, 2023 | americanbankingnews.com

Celldex Therapeutics (NASDAQ:CLDX) Sees Unusually-High Trading Volume

March 23, 2023 | markets.businessinsider.com

LifeSci Capital Reaffirms Their Buy Rating on Celldex (CLDX)

March 26, 2023 | Weiss Ratings (Ad)

Bank Accounts: Frozen!

In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!

March 22, 2023 | markets.businessinsider.com

H.C. Wainwright Keeps Their Buy Rating on Celldex (CLDX)

March 2, 2023 | finanznachrichten.de

Celldex Therapeutics, Inc.: Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update

March 2, 2023 | finance.yahoo.com

Celldex Therapeutics Full Year 2022 Earnings: Revenues Beat Expectations, EPS In Line

March 1, 2023 | finance.yahoo.com

Celldex Reports Fourth Quarter and Year End 2022 Financial Results and Provides Corporate Update

February 27, 2023 | msn.com

Celldex gains 12% on Phase 1 data for urticaria candidate

March 26, 2023 | Weiss Ratings (Ad)

Fed's Shocking New Plan to Control Your Money

The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. 

February 27, 2023 | benzinga.com

Why Celldex Therapeutics Shares Are Trading Higher Today

February 26, 2023 | finance.yahoo.com

Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Spontaneous Urticaria at AAAAI 2023

February 23, 2023 | thestreet.com

Celldex Therapeutics (CLDX) Stock Drops on Change in Phase 3 Enrollment Criteria

February 16, 2023 | finance.yahoo.com

Celldex Therapeutics Announces Appointment of Rita Jain, M.D. to Board of Directors

February 16, 2023 | nasdaq.com

Rtw Investments Now Owns 6.50% of Celldex Therapeutics (CLDX)

February 15, 2023 | finance.yahoo.com

Celldex Therapeutics to Present at SVB Securities Global Biopharma Conference

February 11, 2023 | reuters.com

CLDX.A

February 3, 2023 | finance.yahoo.com

Celldex Therapeutics Announces Upcoming Presentation of Barzolvolimab Phase 1b Results in Chronic Spontaneous Urticaria at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting 2023

January 18, 2023 | finance.yahoo.com

As Celldex Recovers, Here's My Strategy

January 15, 2023 | reuters.com

CLDX.A - | Stock Price & Latest News | Reuters

December 13, 2022 | benzinga.com

BriaCell's Positive Clinical And Quality Of Life Data In Advanced Metastatic Breast Cancer Could Provide Hope For Patients

December 6, 2022 | finance.yahoo.com

Celldex Therapeutics Presents Positive Data from Barzolvolimab Phase 1b Study in Chronic Inducible Urticaria at Global Urticaria Forum 2022

December 3, 2022 | seekingalpha.com

Celldex: Shares Continue To Rally On Barzolvolimab Hope (Technical Analysis)

December 2, 2022 | finance.yahoo.com

Celldex Therapeutics Announces Multiple Upcoming Presentations of Barzolvolimab Data at GA²LEN Global Urticaria Forum (GUF) 2022

November 14, 2022 | markets.businessinsider.com

SVB Securities Keeps Their Buy Rating on Celldex (CLDX)

November 10, 2022 | finance.yahoo.com

Celldex to Participate in Upcoming November Investor Conferences

November 9, 2022 | finance.yahoo.com

Celldex Reports Third Quarter 2022 Financial Results and Provides Corporate Update

November 1, 2022 | finance.yahoo.com

Earnings Preview: Celldex Therapeutics (CLDX) Q3 Earnings Expected to Decline

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive CLDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Celldex Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CLDX Company Calendar

Last Earnings: 11/09/2021
Today: 3/26/2023
Next Earnings (Estimated): 5/04/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Diagnostic substances
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:CLDX
CUSIP: 15117B10
CIK: 744218
Web: www.celldex.com
Phone: (908) 454-7120
Fax: 908-454-1911
Employees: 132
Year Founded: 1983

Price Target and Rating

Average Stock Price Forecast: $66.67
High Stock Price Forecast: $73.00
Low Stock Price Forecast: $63.00
Forecasted Upside/Downside: +82.3%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.39)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-112,320,000.00
Net Margins: -4,765.59%
Pretax Margin: -4,765.59%
Return on Equity: -28.90%
Return on Assets: -26.77%

Debt

Debt-to-Equity Ratio: 0.01
Current Ratio: 17.07
Quick Ratio: 17.07

Sales & Book Value

Annual Sales: $2.36 million
Price / Sales: 731.35
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.93 per share
Price / Book: 5.28

Miscellaneous

Outstanding Shares: 47,210,000
Free Float: 45,932,000
Market Cap: $1.73 billion
Optionable: Optionable
Beta: 2.17

Social Links

Key Executives

Anthony S. Marucci
President, Chief Executive Officer & Director

Sam Martin
CFO, Secretary, Treasurer & Senior Vice President

Tibor Keler
Chief Scientific Officer & Executive VP

Diane C. Young
Chief Medical Officer & Senior Vice President

Elizabeth Crowley
Chief Product Development Officer & Senior VP

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

CLDX Stock - Frequently Asked Questions

Should I buy or sell Celldex Therapeutics stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CLDX shares.
View CLDX analyst ratings or view top-rated stocks.
What is Celldex Therapeutics' stock price forecast for 2023?: 3 brokerages have issued 1 year price targets for Celldex Therapeutics' stock. Their CLDX share price forecasts range from $63.00 to $73.00. On average, they predict the company's share price to reach $66.67 in the next twelve months. This suggests a possible upside of 82.3% from the stock's current price.
View analysts price targets for CLDX or view top-rated stocks among Wall Street analysts.
How have CLDX shares performed in 2023?: Celldex Therapeutics' stock was trading at $44.57 at the beginning of the year. Since then, CLDX shares have decreased by 18.0% and is now trading at $36.56.
View the best growth stocks for 2023 here.
When is Celldex Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our CLDX earnings forecast.
How were Celldex Therapeutics' earnings last quarter?: Celldex Therapeutics, Inc. (NASDAQ:CLDX) issued its earnings results on Tuesday, November, 9th. The biopharmaceutical company reported ($0.45) earnings per share for the quarter, missing the consensus estimate of ($0.36) by $0.09. The biopharmaceutical company had revenue of $0.15 million for the quarter, compared to analysts' expectations of $1.70 million. Celldex Therapeutics had a negative trailing twelve-month return on equity of 28.90% and a negative net margin of 4,765.59%.
What ETFs hold Celldex Therapeutics' stock?: ETFs with the largest weight of Celldex Therapeutics (NASDAQ:CLDX) stock in their portfolio include Alger Mid Cap 40 ETF (FRTY), ALPS Medical Breakthroughs ETF (SBIO), Invesco DWA Healthcare Momentum ETF (PTH), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC) and iShares Micro-Cap ETF (IWC).
When did Celldex Therapeutics' stock split?: Shares of Celldex Therapeutics reverse split before market open on Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 8th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What other stocks do shareholders of Celldex Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include OPKO Health (OPK), Gilead Sciences (GILD), ACADIA Pharmaceuticals (ACAD), Corbus Pharmaceuticals (CRBP), Precigen (PGEN), Micron Technology (MU), Dynavax Technologies (DVAX), Exelixis (EXEL), bluebird bio (BLUE) and SCYNEXIS (SCYX).
What is Celldex Therapeutics' stock symbol?: Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."
Who are Celldex Therapeutics' major shareholders?: Celldex Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Jennison Associates LLC (3.30%), Geode Capital Management LLC (1.88%), Price T Rowe Associates Inc. MD (1.77%), Marshall Wace LLP (1.42%), Eversept Partners LP (1.19%) and Fred Alger Management LLC (1.11%). Insiders that own company stock include Anthony S Marucci, Diane C Young, Elizabeth Crowley, Freddy A Jimenez, James J Marino, Margo Heath-Chiozzi, Richard M Wright, Samuel Bates Martin, Sarah Cavanaugh and Tibor Keler.
View institutional ownership trends.
How do I buy shares of Celldex Therapeutics?: Shares of CLDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Celldex Therapeutics' stock price today?: One share of CLDX stock can currently be purchased for approximately $36.56.
How much money does Celldex Therapeutics make?: Celldex Therapeutics (NASDAQ:CLDX) has a market capitalization of $1.73 billion and generates $2.36 million in revenue each year. The biopharmaceutical company earns $-112,320,000.00 in net income (profit) each year or ($2.39) on an earnings per share basis.
How many employees does Celldex Therapeutics have?: The company employs 132 workers across the globe.
How can I contact Celldex Therapeutics?: Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The official website for the company is www.celldex.com. The biopharmaceutical company can be reached via phone at (908) 454-7120, via email at ir@celldextherapeutics.com, or via fax at 908-454-1911.

This page (NASDAQ:CLDX) was last updated on 3/26/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Celldex Therapeutics - CLDX Stock Forecast, Price & News

Celldex Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Celldex Therapeutics (NASDAQ:CLDX) Stock

CLDX Stock News Headlines

CLDX Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

CLDX Stock - Frequently Asked Questions

Overall MarketRank^™